Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
 shares announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Oct. 25, 2016 -- The Shareholders Foundation, Inc. announces that a deadline is coming up on October 31, 2016 in the lawsuit that was filed for certain investors in shares of American Renal Associates Holdings Inc (NYSE:ARA) over alleged Securities Laws Violations by American Renal Associates Holdings.
The lawsuit seeks to recover damages for certain NYSE:ARA investors.
Investors who purchased shares of American Renal Associates Holdings Inc (NYSE:ARA) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that American Renal Associates Holdings Inc was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for the Company’s dialysis services, that the foregoing scheme was in violation of federal and state laws, and that as a result of the foregoing, American Renal Associates Holdings’ public statements were materially false and misleading at all relevant times.
On August 18, 2016, the Centers for Medicare and Medicaid Services, a federal agency within the U.S. Department of Health and Human Services, announced that it had sent warning letters to all dialysis centers that participate in the federal Medicare program. The Centers for Medicare and Medicaid Services also stated that it is weighing financial penalties on providers found to have directed people eligible for Medicare into Affordable Care Act plans instead—as American Renal is alleged to have done.
Those who purchased American Renal Associates Holdings Inc (NYSE:ARA) shares should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
